"Galectin-3 as a Marker of Subclinical Inflammation in FMF"
NCT ID: NCT06451471
Last Updated: 2024-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
154 participants
OBSERVATIONAL
2021-05-01
2022-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Are serum Galectin-3 levels higher in FMF patients compared to healthy controls?
* Is there a positive correlation between serum Galectin-3 levels and Serum Amyloid A (SAA) protein levels in FMF patients?
Participants will:
* Provide blood samples to measure serum Galectin-3 and SAA levels.
* Complete a sociodemographic and clinical data form.
* Fill out the FMF Quality of Life (QoL) scale.
Researchers will compare FMF patients and healthy controls to see if there are significant differences in serum Galectin-3 levels and to determine the correlation between Galectin-3 and SAA protein levels in FMF patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients
NCT05992727
Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage
NCT04558814
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
NCT05057481
Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spondylitis
NCT05997108
Transcriptional and Immune Parameters of Response to Belimumab
NCT04570306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Comparator: Group 1
PATIENT GROUP DIAGNOSED WITH FMF
No interventions assigned to this group
Active Comparator: Group 2
HEALTHY CONTROL GROUP
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Aged between 18 and 65 years,
2. Able to provide written informed consent for the study,
3. Literate,
4. Diagnosed with Familial Mediterranean Fever (FMF) according to the Tel Hashomer criteria and not currently experiencing an attack (with at least 15 days since the last attack).
<!-- -->
1. Aged between 18 and 65 years,
2. Able to provide written informed consent for the study,
3. Literate.
Exclusion Criteria
2. Presence of known systemic, chronic, severe medical conditions,
3. Presence of active infection,
4. Conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders,
5. Being pregnant or in the lactation period.
1. Presence of known systemic, chronic, severe medical conditions,
2. Presence of inflammatory diseases,
3. Presence of active infection,
4. Conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders,
5. Being pregnant or in the lactation period. -
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turkish League Against Rheumatism
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oguzhan Lacin
Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ataturk University Faculty of Medicine
Erzurum, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRASD-OL-TEZ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.